OverviewSuggest Edit

Ironwood Pharmaceuticals (formerly Microbia) is dedicated to creating, developing, and commercializing innovative human medicines, and has clinical stage programs in GI disorders and dyslipidemia. The Company discovered, developed and is commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood is also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract.

TypePublic
HQCambridge, US
Websiteironwoodpharma.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Feb 2019)730
Job Openings15
Revenue (FY, 2018)$346.6 M(+17%)
Share Price (Mar 2019)$13.4 (-1%)

Key People/Management at Ironwood Pharmaceuticals

Peter Hecht

Peter Hecht

CEO
Brian Cali

Brian Cali

Senior Vice President, R&D Strategy and External Innovation
Gina Consylman

Gina Consylman

Senior Vice President, Chief Financial Officer
Mark Currie

Mark Currie

Senior Vice President, Chief Scientific Officer, and President of R&D
Halley Gilbert

Halley Gilbert

Senior Vice President & Chief Legal Officer
Bill Huyett

Bill Huyett

COO
Show more

Ironwood Pharmaceuticals Office Locations

Ironwood Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
301 Binney St
Show all (1)
Report incorrect company information

Ironwood Pharmaceuticals Financials and Metrics

Ironwood Pharmaceuticals Revenue

Ironwood Pharmaceuticals's revenue was reported to be $346.64 m in FY, 2018
USD

Revenue (FY, 2018)

346.6m

Net income (FY, 2018)

(282.4m)

EBIT (FY, 2018)

(238.9m)

Market capitalization (18-Mar-2019)

2.1b

Closing stock price (18-Mar-2019)

13.4

Cash (31-Dec-2018)

173.2m
Ironwood Pharmaceuticals's current market capitalization is $2.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

22.9m76.4m149.6m274.0m298.3m346.6m

Revenue growth, %

234%96%83%

Cost of goods sold

12.0k

Gross profit

149.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

52.2m65.1m86.8m69.2m81.1m65.7m

Cost of goods sold

2.0m1.9m10.5m12.0k8.2m

General and administrative expense

30.3m29.9m29.3m28.5m30.3m33.0m30.4m36.2m36.9m45.0m55.6m57.8m61.8m61.9m68.4m55.2m

R&D expense

23.0m27.1m22.1m25.1m26.6m28.6m25.8m31.8m31.7m37.5m33.7m37.3m37.1m36.5m38.9m46.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

75.5m74.3m261.3m54.0m125.7m173.2m

Accounts Receivable

513.0k10.0k2.9m933.0k3.2m21.0m

Inventories

22.1m10.6m6.3m1.1m735.0k

Current Assets

229.1m289.7m500.2m380.2m311.6m266.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

144.5m205.1m95.4m51.3m63.7m256.5m248.1m280.9m277.3m182.9m133.3m182.1m162.6m144.8m145.4m141.6m

Accounts Receivable

125.0k13.0k380.0k862.0k1.1m2.6m908.0k1.3m1.2m1.2m4.0m4.3m5.0m6.7m10.2m

Inventories

20.6m23.4m13.0m13.0m5.0m1.5m1.1m479.0k1.7m1.1m76.0k

Current Assets

275.8m371.3m325.8m304.1m263.9m527.0m505.8m495.7m386.1m382.8m357.9m341.5m314.1m275.7m279.5m248.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(272.8m)(189.6m)(142.7m)(81.7m)(116.9m)(282.4m)

Depreciation and Amortization

11.7m12.3m11.6m10.3m8.4m6.1m

Inventories

(11.9m)(3.9m)2.6m(3.1m)346.0k

Accounts Payable

(11.7m)1.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(61.8m)(49.6m)(110.0m)(152.0m)(33.2m)(81.2m)(128.6m)(13.3m)(35.0m)(68.2m)(52.5m)(96.7m)(129.0m)(43.1m)(92.5m)(266.9m)

Depreciation and Amortization

3.1m6.2m9.4m6.0m8.8m2.8m5.3m7.5m2.9m4.8m6.6m1.8m3.5m4.8m

Inventories

(1.3m)272.0k224.0k5.0m4.0k71.0k1.1m1.1m(768.0k)

Accounts Payable

(8.0m)(7.7m)2.8m
USDY, 2018

Revenue/Employee

474.8k
Show all financial metrics
Report incorrect company information

Ironwood Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Ironwood Pharmaceuticals News and Updates

Report incorrect company information

Ironwood Pharmaceuticals Blogs

Ironwood Pharmaceuticals to Present at Cowen Health Care Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 4, 2019-- Ironwood Pharmaceuticals, Inc.  (NASDAQ: IRWD) will present a corporate update at the 39 th Annual Cowen Health Care Conference on Monday, March 11, 2019 at 4:10 p.m. Eastern Time at The Boston Marriott Copley Place in Boston .

Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering

– Proceeds to advance Cyclerion’s soluble guanylate cyclase (sGC) programs targeting breakthrough treatments for serious and orphan diseases – – Spin-off expected to be completed in early April 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 26, 2019-- Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 21, 2019-- Ironwood Pharmaceuticals, Inc.  (NASDAQ: IRWD) will present a corporate update at the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern Time at the Lotte New York Palace in New York .

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update

– Grew 2018 revenue 16% year-over-year to $347 million , driven primarily by U.S. LINZESS ® (linaclotide) collaboration revenue of $264 million and linaclotide API sales of $70 million – – Progressed separation of Ironwood and Cyclerion into two publicly-traded companies with completion expected

Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call

Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call Content Import Mon, 01/28/2019 - 17:03 Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call Jan 28, 2019 This release is a backfill from …

Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation

– Important step toward launching two independent, publicly-traded companies – – Separation on track for first half 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 28, 2019-- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the filing by Cyclerion Therapeutics, Inc.
Show more

Ironwood Pharmaceuticals Frequently Asked Questions

  • Who are Ironwood Pharmaceuticals key executives?

    Ironwood Pharmaceuticals's key executives are Peter Hecht, Brian Cali and Gina Consylman.

  • How many employees does Ironwood Pharmaceuticals have?

    Ironwood Pharmaceuticals has 730 employees.

  • What is Ironwood Pharmaceuticals revenue?

    Latest Ironwood Pharmaceuticals annual revenue is $346.6 m.

  • What is Ironwood Pharmaceuticals revenue per employee?

    Latest Ironwood Pharmaceuticals revenue per employee is $474.8 k.

  • Who are Ironwood Pharmaceuticals competitors?

    Competitors of Ironwood Pharmaceuticals include Reata Pharmaceuticals, Alimera Sciences and Biogen.

  • Where is Ironwood Pharmaceuticals headquarters?

    Ironwood Pharmaceuticals headquarters is located at 301 Binney St, Cambridge.

  • Where are Ironwood Pharmaceuticals offices?

    Ironwood Pharmaceuticals has an office in Cambridge.

  • How many offices does Ironwood Pharmaceuticals have?

    Ironwood Pharmaceuticals has 1 office.